El interés en corto de Design Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Design Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Design Therapeutics (NASDAQ:DSGN) Bolsa, Informe de interés en corto

Design Therapeutics

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEMD

APCX

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DALN

DSGN

ELAB

KULR

LITM

MESO

NVNI

PTPI

QNTM

SGMO

SLXN

VRAX

Acciones de Sangamo Therapeutics suben un 19,5% tras un nuevo acuerdo. Descubre los mayores ganadores y perdedores de hoy.

Acciones de Sangamo Therapeutics (SGMO) suben alrededor de un 20%; 20 acciones que se mueven en el premercado

Design Therapeutics Inc

On Thursday, the House turned down a contingency plan proposed by House Speaker Mike Johnson (R-La.) aimed at averting a government shutdown and suspending the debt limit.
What Happened: Johnson&#8217;s measure, introduced only hours before the vote, failed to secure the necessary two-thirds majority for approval, receiving a 174-235-1 vote, <a href="https://thehill.com/homenews/house/5049768-government-funding-debt-ceiling-bill-fails/">reported</a> The Hill. The bill encountered opposition from Democrats, led by Minority Leader Hakeem Jeffries (N.Y.), along with a few conservative Republicans, mainly due to its inclusion of a two-year debt limit suspension, a provision requested by President-elect Donald Trump.
The future course of action for Johnson remains uncertain. With&nbsp;the Republican opposition, the bill&nbsp;is unlikely to pass if Johnson tries to push it through a regular rule process that only requires a simple majority.
If no legislation is approved by Congress&nbsp;by 11:59 p.m. on Friday,&nbsp;the government will face a shutdown. This failed vote is a setback for Johnson, who is striving to prevent a shutdown by the impending deadline and retain his leadership position in the coming year.

The proposed bill would have maintained the government funding at existing levels through March 14, suspended the debt limit for two years, and allocated approximately $100 billion in disaster relief and about $10 billion for farmer economic assistance.
Despite President-elect Trump&#8217;s endorsement of the package, a few Republicans promptly rejected the legislation. Democrats also overwhelmingly opposed the bill, with lawmakers reportedly chanting &#8220;hell no&#8221; during a closed-door House Democratic Caucus meeting after the bill&#8217;s introduction.
See Also: <a href="https://www.benzinga.com/24/12/42545204/marjorie-taylor-greene-pushes-to-sell-off-usps-amid-doge-momentum-we-need-to-privatize-ive-been-saying-it-for-years?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Marjorie Taylor Greene Pushes To Sell Off USPS Amid DOGE Momentum: &#8216;We Need To Privatize&#8230;I&#8217;ve Been Saying It For Years&#8217;</a>
Why It Matters: Earlier, U.S. Congressional leaders had <a href="https://www.benzinga.com/24/12/42544562/congressional-leaders-reach-bipartisan-deal-to-avert-government-shutdown">reached a bipartisan agreement</a> to extend government funding and avert a shutdown. However, this agreement was rejected by House Republicans under pressure from President-elect Trump, Vivek Ramaswamy and Elon Musk, leading to the current situation. Ramaswamy and Musk are the leaders of the Department of Government Efficiency, a body whose task it is to cut wasteful government spending. 
Trump&#8217;s unexpected dismissal of the bipartisan proposal has escalated the fears of a U.S. government shutdown ahead of Christmas. However, research firm Edward Jones suggests that markets tend to remain positive half the times during past government shutdowns since 1976, despite the short-term volatility introduced by such political events.
House Mike Johnson. Photo via Shutterstock.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

General

House Rejects Trump-Endorsed Backup Plan To Prevent Government Shutdown And Suspend Debt Limit: Lawmakers Chant 'Hell No'

The House Artificial Intelligence Task Force released a report on Tuesday with recommendations on how Congress can boost the development of AI while also protecting against potential risks <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42561047/amazon-meta-alphabet-spotify-lead-jpmorgans-2025-tech-picks-for-ai-potential">of the technology. </a>
The Details: The bipartisan House AI task force, chaired by Rep. Jay Obernolte (R-Calif.), released the 253-page<a href="https://www.speaker.gov/wp-content/uploads/2024/12/AI-Task-Force-Report-FINAL.pdf"> document</a> as the culmination of the group's work which began in February.
Obernolte said the report is just the "beginning of the conversation" around AI policy. 
"It will only be effective if future Congresses implement some of the recommendations that we have created," he added.&nbsp;
Read More: <a href="https://www.benzinga.com/general/social-media/24/12/42598651/mystery-drone-sightings-all-over-the-country-trump-says-what-to-know-about-investigations-lawmakers-reactions">&#8216;Mystery Drone&#8217; Sightings Spark Investigations, Politicians Respond: &#8216;Shoot Them Down,&#8217; Trump Says</a>
The representative said the task force met to consider bills that it could endorse and introduce for passage this Congress, but the group agreed not to do so in order to remain bipartisan. 
"Disagreements started to emerge about the language in each individual bill and we realized that if we wanted to maintain this coalition that was broadly bipartisan … it probably was counterproductive to actually be talking about legislative language," Obernolte said.
The report contains 66 key findings and 89 recommendations across 14 areas and will serve as the foundation for future legislative action on AI. The effects of future AI legislation will ripple across industries, government agencies and individuals.&nbsp;
Why It Matters: The task force wrote in its report that the government should lead by example and foster trust in AI by using the technology to improve efficiency and services while adopting responsible policies surrounding its use.&nbsp;
Companies that are sufficiently large and capable of handling the government's needs, like Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) could benefit from contracts to supply agencies and departments with AI services. 
The House task force also highlighted the importance of promoting AI innovation which may include further legislation like the CHIPS and Science Act, which was designed to promote U.S. semiconductor manufacturing. Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) received more than $7 billion in direct funding and Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) received $6.6 billion in funding from the program.
Another principle the task force emphasized was its duty to protect against AI-related risks and harms. Companies developing large AI models, such as OpenAI and Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) may need to report on training and safety processes if the government determines they could pose security or public health risks. 
The task force also suggested that future Congresses take an "incremental approach" to AI regulation as the technology is rapidly evolving and legislation will need to adapt and evolve as well.&nbsp;
"What we're embracing here is incrementalism. We don't think it's important that everyone agrees on every single aspect of AI immediately," Obernolte said.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42564443/santa-came-early-with-rate-cut-but-federal-reserve-brings-coal-next-year-experts-weigh-in-on-rate-cut-feds-2025-projections">&#8216;Santa Came Early&#8217; But Fed Brings &#8216;Coal Next Year&#8217;: Experts Weigh In On Interest Rate Cut, 2025 Projections</a></li>
</ul>
Photo: Shutterstock

Government

Large Cap

Regulations

Tech

GOOG

GOOGL

INTC

Here's What The Latest Congressional AI Report Could Mean For Big Tech

Residents in one state could lease a new vehicle with a $0 down and $0 a month offer before taxes, in a move that could increase<a href="https://www.benzinga.com/electric-vehicles"> electric vehicle adoption.</a>
 What Happened: With concerns that electric vehicle regulatory credits <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">could disappear</a> under President-elect Donald Trump, residents in the state of Colorado may want to hear more about the latest offer.
The Larry H. Miller Chrysler Dodge Ram FIAT Denver dealership, which sells and leases Stellantis NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) vehicles has a <a href="https://www.lhmchryslerdodgeramfiatdenver.com/fiat-offer.htm">new </a>$0 down, $0 a month offer for the Fiat 500e.
The 27-month lease, with a 10,000 mile per year allowance, has the new offer available to select customers.
Customers will still have to pay taxes on the offer, which total around $1,298 according to an Electrek <a href="https://electrek.co/2024/12/18/crazy-fiat-500e-prices-are-back-you-can-lease-one-for-0-mo-yes-zero-in-co/">report</a>, along with a $395 disposition fee, totaling around $1,693. This calculates out to around $63 per month for a new electric vehicle lease.
Read Also:<a href="https://www.benzinga.com/news/management/24/12/42258470/jeep-marker-stellantis-ceo-carlos-tavares-resigns-amid-falling-us-sales-and-trade-pressures-board-cites-different-views"> Jeep Maker Stellantis&#8217; CEO Carlos Tavares Resigns Amid Falling US Sales And Trade Pressures: Board Cites &#8216;Different Views&#8217; &nbsp;</a>
Why It's Important: The new offer highlights how Colorado is one of the most friendly states when it comes to electric vehicles, which includes $7,500 in state tax credits on select EVs on top of $7,500 in federal tax credits. 
<a href="https://www.benzinga.com/news/23/08/33589652/tesla-vehicle-for-under-15-000-not-yet-but-this-state-has-incentives-to-get-the-price-under-20-000">Benzinga previously reported </a>that combining federal and state credits on a Tesla Model 3 RWD in August 2023 could get the starting price from $40,240 to under $20,000.
"Very compelling," Tesla CEO Elon Musk said at the time. &nbsp;
<a href="https://www.benzinga.com/news/24/07/39677353/electric-vehicle-lease-for-19-a-month-dealership-in-this-state-has-new-offer-to-lure-customers">Benzinga also shared </a>that a Colorado Nissan dealer was offering a $0 down, $ 19 a month offer ($79 per month with fees) on a 2025 Nissan Leaf S earlier this year.
Colorado Gov. Jared Polis made a push to see more electric vehicles sold in the state, with a goal of one million plug-in vehicles on the road by 2030.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42273230/stellantis-market-value-halves-in-2024-why-ceo-tavares-exit-could-take-things-from-bad-to-worse">Stellantis Market Value Halves In 2024: Why CEO Tavares&#8217; Exit Could Take Things From Bad To Worse</a></li>
</ul>
Photo: Fiat 500e, Courtesy Stellantis

STLA

EV Lease Nearly Free With $0 Down, $0 Month Offer In This State

Cansortium Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/TIUM#CSE">TIUM</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTCQB">CNTMF</a>) also known as "FLUENT" and RIV Capital Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/RIV#CSE">RIV</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) announced on Thursday the completion of a previously announced arrangement with RIV Capital whereby FLUENT acquired all of the issued and outstanding Class A common shares of RIV Capital in exchange for FLUENT shares.
Under the terms of the agreement, RIV Capital shareholders received 1.245 of a common share of FLUENT in exchange for each RIV Capital share held. As a result, shareholders of FLUENT hold approximately 51.25% of the combined business of FLUENT and RIV Capital shareholders and The Hawthorne Collective together, hold approximately 48.75% of the combined company, each on a fully diluted basis.
Read Also: <a href="https://www.benzinga.com/24/11/42244572/cannabis-focused-riv-capital-reports-186-yoy-surge-in-q3-revenue-ahead-of-merger-that-will-cover-25-of-us-population">Cannabis-Focused RIV Capital Reports 186% YoY Surge In Q3 Revenue Ahead Of Major Merger That Will Cover 25% Of US Population</a>
The combined company will continue to operate under the FLUENT name. FLUENT shares will continue to trade on the Canadian Securities Exchange under the symbol "TIUM.U" and on the OTCQB Venture Market under the symbol "CNTMF."
Robert Beasley has been named CEO of the combined company. RIV shares were delisted from the CSE at market close on Dec. 19, 2024. The company will cause RIV Capital to apply to the relevant Canadian securities regulatory authorities to cease to be a reporting issuer under applicable Canadian securities laws.
<h1 class="wp-block-heading">Management Commentary</h1>
"I am thrilled to complete this transaction, and I would like to thank our combined teams for all of their hard work over the past few months and our shareholders for their strong support," said Beasley. "Together, we have created one of the most well-positioned cannabis operators in the industry, with a strategic footprint in four key growth markets and a strong balance sheet which will allow us to act on accretive growth opportunities."
Beasley added, "With New York legal retail sales on pace to exceed $1 billion by year-end, our recent successful launch of MOODS in New York underscores the immense potential of the Combined Company, as we have introduced FLUENT's brands to scale the wholesale operations and gain additional shelf space in dispensaries across the state."
David Vautrin, former chief revenue officer and interim CEO of RIV Capital and, upon closing, now chief commercial officer of FLUENT called the deal transformational.
"This is a transformational deal for RIV Capital and represents the culmination of substantial work for both FLUENT and RIV Capital," Vautrin said. "As evidenced by past performance, we believe FLUENT is one of the most fundamentally sound and now one of the most well-positioned multi-state operators in the US.."
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/12/42597912/pesticides-in-pot-the-overlooked-dangers-of-californias-legal-weed">Pesticides In Pot: Overlooked Dangers Of California&#8217;s Legal Weed</a></li>
</ul>
Courtesy photo

Cannabis

Retail Sales

CNPOF

CNTMF

CSE:RIV

CSE:TIUM

Cansortium Completes RIV Capital Acquisition, Adding New York Retail, Wholesale, Cannabis Cultivation Operations

IONS

Trading Halt: Halt status updated at 6:55:00 PM ET: Quotation Resumption: News and Resumption Times

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) hit new yearly highs recently as the overall cryptocurrency sector has traded higher since Donald Trump won the<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41778425/bitcoins-all-time-high-a-groundbreaking-milestone-and-strong-post-election-rally-coming-ex"> 2024 presidential election.</a>
A new Benzinga poll asks readers if Dogecoin will trade closer to levels seen before the election or all-time highs set back in 2021.
What Happened: Dogecoin traded between 15 cents and 18 cents on Nov. 5, the day of the U.S. presidential election. Like many cryptocurrencies, Dogecoin <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41890024/much-wow-dogecoin-is-now-larger-than-ford-adidas-lululemon-roblox-15-companies-worth-less-than-meme-crypto">gained in the days </a>and weeks after Trump's victory.
Helped by Trump's victory, optimism for a pro-crypto White House administration and the appointment of Dogecoin supporter Elon Musk as head of the Department of Government Efficiency, or D.O.G.E. for short, the meme cryptocurrency hit new <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42274989/dogecoins-insane-165-growth-in-november-is-just-the-first-candle-traders-speculate">yearly highs in November </a>and December.
Benzinga recently asked if the recent momentum in Dogecoin and future optimism would see Dogecoin more likely to trade closer to an all-time high of $0.7376 set in May 2021 or back to the $0.25 level last seen on Nov. 10 shortly after the election.
"Which level is Dogecoin more likely to reach next: 69 cents or 25 cents?" Benzinga asked.
The results were:
<ul>
<li>69 Cents: 78%</li>
<li>25 Cents: 22%</li>
</ul>
The poll found over three-fourths of readers predict Dogecoin is more likely to hit 69 cents before hitting 25 cents again.
This would suggest that Dogecoin has more gains ahead and would set new 52-week highs and get close to all-time highs.
The last time Dogecoin hit 69 cents was on May 9, 2021, the day after the all-time high was set. Dogecoin traded at 69 cents or higher on four occasions in May 2021.
Dogecoin has traded between $0.07497 and $0.4835 over the [ast year, with the high set in early December.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41908812/if-you-invested-100-in-dogecoin-when-the-meme-coin-launched-heres-how-much-youd-have-today">If You Invested $100 In Dogecoin When The Meme Coin Launched, Here&#8217;s How Much You&#8217;d Have Today</a>
Why It's Important: Recent polls have shown continued optimism for Dogecoin, which is one of the 10 most valuable cryptocurrencies by market capitalization.
A recent <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41945659/dogecoin-to-69-cents-or-1-benzinga-readers-predict-how-high-it-could-fly-by-end-of-2024">November Benzinga poll</a> asked what Dogecoin's highest price by the end of 2024 would be.  
The results were:
<ul>
<li>42 cents: 10%</li>
<li>69 cents: 24%</li>
<li>New All-Time Highs (73.77 cents): 18%</li>
<li>$1.00: 17%</li>
<li>None of the above: 31%</li>
</ul>
The highest percentage of readers thought that none of the price targets would be reached by Dogecoin. The next highest result was 69 cents, which would take Dogecoin close to all-time highs and a memeable number before year-end.
Only 18% of readers think that Dogecoin will reach all-time highs before the end of the year, and a lower percentage (17%) believe Dogecoin will hit a price of $1.
<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42378513/can-bitcoin-ethereum-dogecoin-shiba-inu-or-solana-beat-xrp-in-2025-poll-says-yes-one-coin-stands-out">A December poll </a>asked if any of the top cryptocurrencies could outperform fast-moving XRP in 2025. The possible answers were Bitcoin, Solana, Dogecoin, Ethereum, Shiba Inu, Hedera or none of the above, meaning XRP would be the top gainer in 2025.
Dogecoin ranked fourth in the poll at 13%, with Bitcoin won the poll at 28%, followed by None of the Above at 24% and Solana at 15%.
DOGE Price Action: Dogecoin trades at $0.3205 at the time of writing, down 11% over the last 24 hours and down 17% over the past month. Despite the recent drop in price, the price of Dogecoin is up over 240% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42440369/bitcoins-next-move-105000-or-85000-poll-finds-over-60-say">Bitcoin&#8217;s Next Move: $105,000 Or $85,000? Poll Finds Over 60% Say…</a></li>
</ul>
The study was conducted by Benzinga from Dec. 11 through Dec. 12, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 123 adults.
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

$DOGE

Dogecoin Down 17% In One Month, Will Meme Crypto Reach 25 Cents Or 69 Cents First? 78% Of Readers Say…

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has outperformed the market over the past 10 years by 11.19% on an annualized basis producing an average annual return of 22.11%. Currently, Meta Platforms has a market capitalization of $1.51 trillion. 
Buying $1000 In META: If an investor had bought $1000 of META stock 10 years ago, it would be worth $7,388.29 today based on a price of $597.04 for META at the time of writing.
<h3>Meta Platforms's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734651910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Meta Platforms 10 Years Ago Would Be Worth This Much Today

The debate over how to tackle America's obesity epidemic that affects 40% of adults and nearly<a href="https://www.benzinga.com/general/biotech/24/02/37157967/whats-gaining-popularity-among-us-teens-battling-obesity-novo-nordisks-weight-loss-drug-wegovy" target="_blank" rel="noreferrer noopener">&nbsp;20% of children</a>, has sparked contrasting views from two influential voices in President-elect Donald J. Trump's orbit. The side that wins could have a lasting impact on public health in the U.S.
Robert F. Kennedy Jr., <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">Trump's pick</a> for secretary of Health and Human Services (HHS), says lifestyle changes need to be a big part of the solution.
Elon Musk, billionaire tech entrepreneur and seemingly one of Trump's closest advisers, is calling for easier access to weight loss drugs such as <a href="https://www.benzinga.com/topic/ozempic">Ozempic</a> and <a href="https://www.benzinga.com/topic/wegovy">Wegovy</a>, produced by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>). Musk, who has used Wegovy, said on X that &#8220;nothing else is even close&#8221; when considering how to address obesity, <a href="https://www.nytimes.com/2024/12/18/health/ozempic-food-rfk-elon-musk.html">noted</a> the New York Times. "Nothing would do more to improve the health, lifespan, and quality of life for Americans than making GLP inhibitors super low cost to the public."
Kennedy, meanwhile, says if approved to lead the HHS, he'll roll out an anti-obesity plan that will focus on healthier nutrition and encouraging Americans to make time for daily exercise. Kennedy told Fox News' Greg Gutfeld before the election that the makers of obesity drugs are &#8220;counting on selling it to Americans because we're so stupid and so addicted to drugs.&#8221;
<h1 class="wp-block-heading">Suicide and Ozempic?</h1>
Kennedy <a href="https://www.youtube.com/watch?v=qX9nQ40mSMY">said in the same Fox News appearance</a> that the European Union "is right now investigating Ozempic for suicidal ideation," although the EU regulator concluded in April that available evidence does not suggest Ozempic and other weight-loss drugs cause suicidal thoughts or actions.
Dr. Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota says such confident although false or misleading assertions are Kennedy's trademark. And they can be dangerous, Osterholm warned, when applied to public health bedrocks like vaccines.
"He acts like he knows what he's talking about when he doesn't, and he says things with a definition that makes people convinced he has the data to support his statement," Osterholm <a href="https://www.cnn.com/2024/11/17/health/rfk-jr-ozempic/index.html">told</a> CNN two weeks after the November election. "Trying to follow him and understand what he's talking about is often like trying to nail Jell-O to the wall."
Kennedy and Musk's competing perspectives underscore the difficult path toward dealing with the U.S.'s <a href="https://www.benzinga.com/news/24/03/37413349/ozempic-wegovy-other-weight-loss-drugs-wont-solve-global-obesity-crisis-affecting-1b-people-who-warn" target="_blank" rel="noreferrer noopener">severe obesity epidemic</a>: lifestyle changes vs. pharmaceuticals.
<h1 class="wp-block-heading">Cannabis a Solution?</h1>
Some people may look to <a href="https://www.benzinga.com/cannabis">cannabis</a> for a natural solution. Recent studies have <a href="https://www.nature.com/articles/s41366-023-01399-x" target="_blank" rel="noreferrer noopener">suggested</a> &#8220;cannabis and subproducts could be considered adjuncts in obesity treatment by helping to reduce relevant anthropometric measurements.&#8221;
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42491683/rfk-jrs-lawyer-urges-fda-to-revoke-polio-vaccine-approval-endangering-millions-of-children">Kennedy&#8217;s Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children</a></li>
</ul>

Health Care

Elon Musk Vs. RFK Jr.: Obesity Crisis Debate Sparks Struggle For Trump's Influence

Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) has outperformed the market over the past 20 years by 1.81% on an annualized basis producing an average annual return of 10.01%. Currently, Nike has a market capitalization of $115.16 billion. 
Buying $1000 In NKE: If an investor had bought $1000 of NKE stock 20 years ago, it would be worth $6,789.21 today based on a price of $77.37 for NKE at the time of writing.
<h3>Nike's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734651013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Nike 20 Years Ago Would Be Worth This Much Today

Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) has outperformed the market over the past 15 years by 14.86% on an annualized basis producing an average annual return of 26.48%. Currently, Chipotle Mexican Grill has a market capitalization of $84.14 billion. 
Buying $1000 In CMG: If an investor had bought $1000 of CMG stock 15 years ago, it would be worth $34,170.91 today based on a price of $61.75 for CMG at the time of writing.
<h3>Chipotle Mexican Grill's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734650109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Chipotle Mexican Grill Stock In The Last 15 Years

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 4.07% on an annualized basis producing an average annual return of 15.69%. Currently, Verisk Analytics has a market capitalization of $38.91 billion. 
Buying $100 In VRSK: If an investor had bought $100 of VRSK stock 15 years ago, it would be worth $894.74 today based on a price of $275.58 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734649208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRSK

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Jones Lang LaSalle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) has outperformed the market over the past 20 years by 1.69% on an annualized basis producing an average annual return of 9.89%. Currently, Jones Lang LaSalle has a market capitalization of $11.72 billion. 
Buying $1000 In JLL: If an investor had bought $1000 of JLL stock 20 years ago, it would be worth $6,666.58 today based on a price of $246.93 for JLL at the time of writing.
<h3>Jones Lang LaSalle's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734648313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Jones Lang LaSalle 20 Years Ago Would Be Worth This Much Today

BlackBerry Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported third-quarter financial results after the market close on Thursday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/24/12/ac42605872/blackberry-reports-third-quarter-fiscal-year-2025-results">from the quarter</a>.
Q3 Earnings: BlackBerry reported third-quarter revenue of $162 million. The company reported third-quarter adjusted earnings of two cents per share, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> for a loss of one cent per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
IoT revenue was&nbsp;$62&nbsp;million, up 13% year-over-year.&nbsp;Cybersecurity revenue totaled $93&nbsp;million in the quarter, up 7% year-over-year. Licensing revenue&nbsp;came in at $7&nbsp;million.
Total company gross margin was 74% in the quarter. Operating cash flow improved by $34 million year-over-year to $3 million. BlackBerry ended the quarter with $266 million in&nbsp;cash, cash equivalents and&nbsp;short-&nbsp;and long-term investments.
&#8220;BlackBerry achieved a significant inflection in its results this past quarter. Driven by a combination of strong revenue performance for both our Cybersecurity and IoT divisions, and continued focus on costs and efficiency, the company delivered stronger than expected profitability and a return to positive cash flow ahead of schedule,&#8221; said John Giamatteo, CEO of BlackBerry. 
From Last Week: <a href="https://www.benzinga.com/24/12/42477300/russian-state-backed-hackers-target-ukrainian-military-devices-via-spacexs-starlink-microsoft-report-reveals">Russian State-Backed Hackers Target Ukrainian Military Devices Via SpaceX&#8217;s Starlink, Microsoft Reveals</a>
Guidance: BlackBerry expects fourth-quarter revenue of $126 million to $135 million versus estimates of $161.49 million. The company anticipates fourth-quarter IoT revenue of $60 million to $65 million, secure communications revenue of $62 million to $66 million and licensing and other revenue of approximately $4 million.
BlackBerry expects full-year revenue of $517 million to $526 million versus estimates of $603.12 million. The company anticipates full-year adjusted earnings to be somewhere between breakeven and a loss of two cents per share, versus estimates for a loss of two cents per share.
Management will further discuss the quarter on a call with investors and analysts at 5:30 p.m. ET.
BB Price Action:&nbsp;<a href="https://www.benzinga.com/quote/BB" target="_blank" rel="noreferrer noopener">BlackBerry shares</a>&nbsp;were up 0.17% in after hours, trading at $2.98 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of BlackBerry.

Earnings

BlackBerry Beats Q3 Earnings Estimates, But Soft Guidance Keeps Shares In Check

Legal

SVCO

Silvaco Says US Court Of Appeals For The Ninth Circuit Affirmed US District Court's Dismissal Of All Claims Brought By Aldini

ALLETE Says FERC Approved Proposed Transaction With CPP Investments And Global Infrastructure Partners

Guidance

PARR

Par Pacific Expects 2025 Capital Expenditure And Turnaround Outlay Guidance Of $210M - $240M

Marsh &amp; McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 10 years by 2.76% on an annualized basis producing an average annual return of 13.69%. Currently, Marsh &amp; McLennan has a market capitalization of $103.31 billion. 
Buying $100 In MMC: If an investor had bought $100 of MMC stock 10 years ago, it would be worth $360.25 today based on a price of $210.35 for MMC at the time of writing.
<h3>Marsh &amp; McLennan's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734647416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Marsh & McLennan 10 Years Ago Would Be Worth Today

SPRY

ARS Pharmaceuticals Says Express Scripts Has Added neffy (Epinephrine Nasal Spray) To Its Commercial National Formularies

The Stock Repurchase Program will begin on December 19, 2024 and conclude on December 19, 2025.

Buybacks

FRST

Primis Financial Board Approves Stock Repurchase Program For Up To 740,600 Of Outstanding Shares Of Common Stock

As a result of this error, the Bank will record $8.1 million on a pre-tax basis of occupancy expense in the fourth quarter of 2024. On an after-tax basis, this will reduce fourth quarter diluted earnings per share by approximately $0.43.
As for the impact of ASC 842 in future years, it is expected that the correct calculation of lease expense will increase occupancy expense by approximately $1.6 million per year on a pre-tax basis.
It has evaluated the impact to income for each of the periods involved as well as the cumulative impact to 2024's results and have determined the understatement in the prior years as well as the impact to the results for 2024 are not material to the Bank's results of operations or its balance sheet.

PFBC

Preferred Bank Finds Unreconciled Difference In Its Calculation Of Its Right Of Use Asset And Lease Liabilities; Expects Additional Q4 Expense To Reduce Q4 EPS By $0.43

Larimar stock rallies 24% on FDA removal of partial clinical hold

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
<a href="https://investorplace.com/industries/healthcare/biotech/">Biotech stocks</a> are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company. Millions of dollars, partnerships with big-name pharmaceuticals, or even a buyout can follow. However it entails a lot of risk. The Piper Sandler (NYSE:<a href="https://investorplace.com/stock-quotes/pipr-stock-quote/">PIPR</a>) investment firm says it found three biotech stocks with the winning ticket. These Piper Sandler stocks have investors curious. 



Piper Sandler may be the best bet for investors especially when you see where things are for biotech companies. The breakthrough drug discovery process can fail miserably. According to the American Society for Biochemistry and Molecular Biology, <a href="https://www.asbmb.org/asbmb-today/opinions/031222/90-of-drugs-fail-clinical-trials#:~:text=It%20takes%2010%20to%2015,candidates%20in%20clinical%20trials%20fail.">90% of all drug candidates</a> in clinical trials fail. Ouch!



Despite spending $1 billion on average, and waiting 10 to 15 years, most biotechs come up with nothing. That&rsquo;s why when they do succeed it is like hitting the lottery, because they have.



Piper Sandler believes they can post triple-digit returns over the next year. These Piper Sandler stocks are expected to grow by at least 100% in the next 12 months. Let&rsquo;s see why they feel confident these Piper Sandler stocks will double in price.



<h2>Piper Sandler Stocks to Buy: Context Therapeutics (CNTX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/orthopedic-therapy-1600-imac-300x169.png" alt="Physiotherapist doing healing treatment on patient leg. Therapist wearing blue uniform. Osteopathy, Chiropractic leg adjustment. Orthopedic therapy. ATIP stck."><div>Source: Microgen / Shutterstock</div></div>Context Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cntx-stock-quote/">CNTX</a>) is already off to the races. The biotech is up 80% so far in 2024 and has more than tripled over the past 12 months. Piper Sandler analyst Joseph Catanzaro initiated coverage of the stock last week with an overweight rating and set a market-high $4.50 per share one-year target price. Context stock currently trades around $2 per share, indicating 125% upside potential.



The analyst highlighted the potential of Context Therapeutics&rsquo; lead drug candidate, CTIM-76, which targets Claudin6 (CLDN6) in solid tumors. CLDN6 is one of the 27 family members of claudins that play an important role in tight adherence epithelial cell sheets that plays a significant role in cancer start and progression.



According to Investing.com CTIM-76 shows indications it <a href="https://www.investing.com/news/company-news/piper-sandler-bullish-on-context-therapeutics-stock-cites-ctim76-program-93CH-3443404">could be effective against</a> a broad range of CLDN6 expressions. That might let it be an effective therapy against different types of cancer, including ovarian and non-small cell lung cancer. Piper Sandler was bullish about the treatment&rsquo;s prospects heading into clinical testing.



Of course, Context Therapeutics is a pre-revenue stage company so its stock is going to be volatile but the market is backing this stock today.



<h2>Revance Therapeutics (RVNC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/health-medical-heart-1600-300x169.jpg" alt="hands holding a red heart shape against blue background symbolizing health"><div>Source: shutterstock.com/Anastasia Zagoruyko</div></div>Analyst David Amsellem reiterated his overweight rating of Revance Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvnc-stock-quote/">RVNC</a>) though he lowered the one-year price target from $20 per share to $11 per share. That is still a 263% implied upside in the stock price.



Unlike Context Therapeutics, Revance does generate revenue from the sale of Daxxify, an alternative to the better known Botox made by AbbVie (NYSE:<a href="https://investorplace.com/stock-quotes/abbv-stock-quote/">ABBV</a>). The treatment lasts between six months and nine months whereas Botox averages three to four months.



First-quarter <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479290/000147929024000099/rvnc-20240509.htm">revenue jumped 13%</a> to $51.9 million on higher Daxxify sales, which hit $22 million. Botox generates about $2 billion annually for AbbVie. Revance generated $29 million in sales of its RHA Collection, or Resilient Hyaluronic Acid, the only hyaluronic acid filler approved by the FDA for dynamic facial lines, wrinkles and folds. Daxxify is now also FDA-approved for the treatment of adults with cervical dystonia, a painful condition that causes the neck muscles to contract involuntarily, which causes the head to twist or turn to one side.



However, Revance stock has been on a long slide lower. Shares are down 65% in 2024 and over 90% for the past year. The stock collapsed after Revance posted bigger than expected losses last year and then continued falling after the biotech said it was <a href="https://www.investors.com/news/technology/rvnc-stock-collapses-as-prestige-plan-goes-up-in-smoke/">cutting prices on Daxxify</a> to better compete against Botox. It likely plays into why the Piper Sandler analyst nearly halved his price target.



<h2>Design Therapeutics (DSGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/healthcare1600a-300x169.jpg" alt="stethoscope on a stock chart representing healthcare stocks to buy. Healthcare Stocks"><div>Source: Shutterstock</div></div>Design Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsgn-stock-quote/">DSGN</a>) went the other way when analyst Yasmeen Rahimi doubled her price target from $6 per share to $12 per share. She also upgraded her rating from neutral to overweight. Rahimi says the biotech has a diversified and innovative pipeline that provides a solid foundation for future growth.&nbsp;Trading at around $4.50 per share, the price target implies 167% growth ahead.



The analyst maintains the stock is value-priced yet offers solid financials and sufficient cash on hand to finance its drug development program. She believes the outlook for that program is positive, with promising outcomes for its DT-216P2, DT-168, and the upcoming drug candidates for Huntington&rsquo;s disease and myotonic dystrophy 1.



&#8203;&#8203;DT-216P2 is for the treatment of Friedreich Ataxia, a hereditary disorder that affects some of the body&rsquo;s nerves. DT-168 is for Fuchs endothelial corneal dystrophy, an eye disease that attacks the endothelial layer of the cornea.



Shares of Design Therapeutics are up 69% in 2024.



On the date of publication, Rich Duprey held a LONG position in ABBV stock. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/the-100-club-piper-sandlers-3-top-picks-for-triple-digit-gains/">The 100%+ Club: Piper Sandler&#8217;s 3 Top Picks for Triple-Digit Gains</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

Lexeo stock drops 24% amid Friedreich Ataxia study results

Design Therapeutics GAAP EPS of -$0.21

RBC Capital analyst Leonid Timashev maintained a Hold rating on Design Therapeutics (DSGN – Research Report) yesterday and set a price target of $4...

RBC Capital Sticks to Their Hold Rating for Design Therapeutics (DSGN)

Leerink Partners analyst Joseph Schwartz has reiterated their neutral stance on DSGN stock, giving a Hold rating on August 5. Joseph Schwartz has g...

Design Therapeutics: A Cautious Hold Amidst Financial Stability and Clinical Progress

RBC Capital Remains a Hold on Design Therapeutics (DSGN)

Design Therapeutics GAAP EPS of -$0.23 beats by $0.02

Leerink Partners analyst Joseph Schwartz reiterated a Hold rating on Design Therapeutics (DSGN – Research Report) on November 7 and set a price tar...

Cautious Optimism for Design Therapeutics Amid Promising Developments and Financial Challenges

ABBV

ALPMF

ALPMY

BIIB

CNTX

LRMR

LXEO

PIPR

PRME

PTCT

RVNC

SLDB

VYGR

Press Releases

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Comments

Design Therapeutics

Interés en corto

Design Therapeutics (NASDAQ:DSGN) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL